We determined that 85 ,iM aphidicolin was sufficient to block macroscopic plaque formation by vaccinia virus and to cause a 104-fold reduction in viral yield from a wild-type infection. A chemically mutagenized viral stock was passaged sequentially in the presence of drug, and plaque-purified viral stocks resistant to aphidicolin were isolated and characterized. By use of a marker rescue protocol, the lesion in each mutant was found to map within the same 500-bp fragment within the DNA polymerase gene. All of the mutants were found to contain a single nucleotide change in the same codon. In nine of these mutants, the alanine residue at position 498 was changed to a threonine, whereas a 10th mutant sustained a valine substitution at this position. Congenic viral strains which carried the Aphr lesion in an unmutagenized wild-type background were isolated. The Thr and Val mutations were found to confer equivalent levels of drug resistance. In the presence of drug, viral yields were 25% of control levels, and the levels of viral DNA synthesized were 30 to 50% of those seen in control infections. The two mutations also conferred an equivalent hypersensitivity to the cytosine analog 1-0-D-arabinofuranosylcytosine (araC); strains carrying the Thr mutation were moderately hypersensitive to the pyrophosphate analog phosphonoacetic acid and the adenosine analog araA, whereas the Val mutation conferred acute hypersensitivity to these inhibitors. The Val mutation also conferred a mutator phenotype, leading to a 20-to 40-fold increase in the frequency of spontaneous mutations within the viral stock.
1-0-D-arabinofuranosylcytosine (araC); strains carrying the Thr mutation were moderately hypersensitive to the pyrophosphate analog phosphonoacetic acid and the adenosine analog araA, whereas the Val mutation conferred acute hypersensitivity to these inhibitors. The Val mutation also conferred a mutator phenotype, leading to a 20-to 40-fold increase in the frequency of spontaneous mutations within the viral stock.
Vaccinia virus displays an unusual degree of physical and genetic autonomy from host cell functions. Indeed, the virus is presumed to encode all of the proteins required for replication and transcription of the 192-kb DNA genome. The genetic complexity and cytoplasmic localization of the virus make it a superb model system for detailed studies of nucleic acid metabolism. Pursuant to our efforts to study the replication machinery encoded by vaccinia virus, we have undertaken the isolation and characterization of viral mutants with conditionally lethal and drug-resistant lesions in the DNA polymerase.
The 1,006-amino-acid DNA polymerase contains polymerase and proofreading exonuclease activities and retains the conserved sequences shared among numerous viral (phi-29, T4, adenovirus, vaccinia virus, herpes simplex viruses types 1 and 2 [HSV-1 and -2], Epstein-Barr virus, and cytomegalovirus) and eucaryotic (human a and yeast pol I) polymerases (3, 4, 12, 24, 27, 43, 44) . These homologies are thought to mark functional domains involved in template or substrate binding and/or catalytic activity. To date, two temperaturesensitive (codons 392 and 611), one phosphonoacetic acidresistant (PAA), and one aphidicolin-resistant (Aphr) lesion have been localized to specific codons of the viral polymerase (10, 12, 38, 39) . The repeated recovery of the same PAAr lesion (codon 372, G -* D) in several independent selections suggests that this lesion may identify the site of the enzyme's interaction with PAA, an inhibitor of pyrophosphate exchange. Aphidicolin, a fungal tetracyclic diterpenoid, is a specific inhibitor of members of the DNA polymerase a family. Its inhibitory action stems from its presumed interaction with nucleotide-binding domains; biochemical studies * Corresponding author.
have indicated that aphidicolin acts as a competitive inhibitor with respect to dCTP and a noncompetitive inhibitor with respect to dATP, dGTP, and TTP in its interactions with the viral enzyme (34) . The one known Aphr lesion identified within a mutated vaccinia virus DNA polymerase (codon 670) (10) maps within conserved domain III shared by various replicative polymerases (43, 44) . In light of the close association of aphidicolin with the nucleotide-binding domain of several polymerases, we have pursued the isolation of additional Aphr mutants in an effort to probe the interaction of the viral polymerase with its substrates. (Waterbury, Conn.). Aphidicolin and rifampin were prepared as 10 mM and 25-mg/ml stocks, respectively, in dimethyl sulfoxide and stored at -20°C. PAA was prepared as a 10-mg/ml stock in distilled water, adjusted to pH 7.0, and stored at 4°C. AraC and araA were prepared as 1 mM stocks in phosphate-buffered saline (PBS), pH 7.4, and stored at -80°C. MNNG was prepared as a 1-mg/ml stock in 10 mM Tris buffer, pH 7.3, and stored at -20°C. IBT was prepared fresh just before use by first dissolving it in acetone to 5 mg/ml and then diluting it to 1 mg/ml with 4 volumes of 0.25 M NaOH. Each drug was diluted to its final concentration in Dulbecco modified Eagle medium (DMEM) with 5% fetal calf serum (FCS) just before use.
Determination of viral yields. Viral titers were determined by plaque assay as follows. Following at least two cycles of freeze-thaw to release virus from infected cells and two 15-s bursts of sonication, virus preparations were serially diluted in DMEM and plated on monolayers of BSC40 cells. Following a 1-h adsorption period, the inoculum was removed and the cells were fed with DMEM-5% FCS with or without any drugs. After 48 h of incubation at 37°C, the plates were fixed and stained with 0.1% crystal violet, and plaques were counted manually.
Mutagenesis. Confluent monolayers of BSC40 cells (150-cm2 flasks) were infected with wt virus at a multiplicity of infection (MOI) of 10 PFU per cell. After 30 min of adsorption at 32°C, the inoculum was removed and the monolayers were rinsed once with DMEM and fed with DMEM-5% FCS containing MNNG at 5 ,ug/ml. After 10 h of incubation at 32°C, the medium was removed. The cells were then rinsed twice with DMEM, fed with MNNG-free medium, and returned to 32°C (8) . At 48 h postinfection (p.i.), cells were scraped from the flask, collected by centrifugation, and resuspended in 2 ml of PBS. Virus was released from cells by two cycles of freeze-thaw and stored at -80°C. For comparative purposes, a nonmutagenized control stock was similarly prepared.
Isolation of aphidicolin-resistant mutants. Mutants were selected by serial passage of mutagenized virus through BSC40 cells in the presence of 85 ,uM aphidicolin at 32°C. The initial passage was performed by infecting a BSC40 monolayer with mutagenized vaccinia virus at an MOI of 0.5; following a 60-min adsorption period, the inoculum was removed and the monolayer was fed with DMEM-5% FCS containing 85 ,uM aphidicolin. After 3 days of incubation, cells were scraped from the plates, collected by centrifugation, and resuspended in 1 ml of PBS. Virus was released from cells by two cycles of freeze-thaw. Three subsequent passages were performed in this manner, except that (i) the inoculum for passages 2 and 3 consisted of one-fifth of the harvest of the previous passage, which in retrospect corresponded to MOIs of 0.1 and 0.3, respectively; (ii) passage 4 was performed at an MOI of 0.15; and (iii) incubation of passages 2, 3, and 4 was for 5 days. Yields of total and aphidicolin-resistant virus from each passage were determined by plaque assay at 37°C in the absence or presence of aphidicolin, respectively.
The yield from passage 4 was used as the inoculum for plaque purification of several drug-resistant mutants. BSC40 monolayers were infected with approximately 10 PFU from passage 4 and overlaid with DMEM-5% FCS containing 0.8% agarose and 85 ,iM aphidicolin. After 6 days of incubation at 32°C, monolayers were stained with 0.01% neutral red in PBS for several hours. Following removal of the neutral red solution, well-isolated plaques were picked with sterile pasteur pipettes and suspended in 100 IlI of PBS.
Following two cycles of freeze-thaw and two 15-s bursts of sonication, plaque suspensions were used to infect fresh monolayers for a second plaque purification under agarose. Well-isolated plaques were picked and stored as described above. Ten such isolates (AR n) were amplified on BSC40 cells in the presence of aphidicolin. Cells were scraped from 15-cm dishes, collected by centrifugation, and resuspended in 1 ml of PBS. The titer of each stock was determined by plaque assay in the presence or absence of aphidicolin.
DNA preparation and molecular cloning. Genomic DNA from each Aphr isolate was obtained by harvesting monolayers of infected cells at the point of maximal cytopathic effect. After lysis of the cells by hypotonic swelling, the nuclei were removed by low-speed centrifugation and the viral cores were then collected by sedimentation. Viral DNA was then purified as described elsewhere (39) (13) . At 15 h p.i., aphidicolin at 85 jiM was added to the dishes. (For rescues in which 500-bp DNA fragments were used, the precipitate-containing medium was removed and monolayers were rinsed once with fresh DMEM-5% FCS prior to being refed with DMEM-5% FCS containing 85 ,uM aphidicolin.) Plates were incubated an additional 2 or 3 days at 37°C and then harvested and titrated as described above.
Isolation of viral isolates carrying the individual aphidicolinresistant mutations in a wt genomic background. Plaquepurified Aphr isolates were obtained from wt-infected monolayers individually transfected with the minimal 500-bp fragment cloned from the genomes of five Aphr mutants and shown to carry the Aphr lesion (see above and Table 1 ). Serial dilutions of these crude marker rescue stocks were applied to monolayers, and Aphr isolates were obtained by plaque purification under agarose at 37°C in the presence of aphidicolin. From each of the five infection-transfections, two well-isolated plaques were picked, subjected to a second round of plaque purification, and amplified through BSC40 cells to generate crude viral stocks (extracts from infected monolayers, 15-cm-diameter dishes). The second plaque purification and subsequent amplification of the virus was done in the presence of aphidicolin for one isolate (ARP-n+) from a marker rescue and in the absence of aphidicolin for the other isolate (ARP-n) from that rescue.
DNA sequencing. Plasmids were digested with the appropriate restriction enzyme and then either end labeled at the 3' terminus with the Klenow fragment of DNA polymerase I and the appropriate a-32P-deoxynucleoside triphosphate or at the 5' terminus with polynucleotide kinase and [-y-32P]ATP after dephosphorylation with calf intestine alkaline phosphatase. Radiolabeled DNA was then subdigested to yield a DNA fragment labeled at a single terminus; fragments were purified by glass powder purification after agarose gel electrophoresis. Labeled fragments were sequenced by the J. VIROL.
VACCINIA VIRUS DNA POLYMERASE 871 Maxam-Gilbert chemical degradation procedure (30) . Except where indicated, sequences were obtained for both strands.
Determination of viral yield in single-step growth experiments. Viral yields from a single round of infection were determined as follows. Confluent dishes of BSC40 cells were infected with wt or mutant virus at an MOI of 0.3 or 1.0, as indicated in the figure legends. Following a 1-h adsorption period in DMEM at 37°C, the inoculum was removed and monolayers were fed with DMEM-5% FCS containing various concentrations of aphidicolin, PAA, araC, or araA. At 24 h p.i., cells were harvested by scraping plates with a rubber policeman, collected by low-speed centrifugation, and resuspended in 10 mM Tris buffer (pH 9.0). Following two cycles of freeze-thaw to release virus from the cells, viral yields were determined by plaque assay in the absence of drugs.
Quantitation of viral DNA replication by dot blot hybridization. Confluent 35-mm dishes of BSC40 cells were infected with wt or mutant virus at an MOI of 5 PFU-cell. After a 30-min adsorption period at 37°C, the inoculum was removed and cultures were rinsed and fed with DMEM-5% FCS with or without aphidicolin at 85 ,uM and then incubated for various times at 37°C. Cell lysates were then prepared, blotted to Zeta-probe membranes (Bio-Rad Laboratories, Richmond, Calif.), and hybridized with viral probes prepared by nick translation (36) as previously described (35) .
RESULTS

Dose-dependent inhibition of vaccinia virus replication by
aphidicolin. In order to optimize conditions for the isolation of resistant viral isolates, the dose dependency of the inhibitory effect of aphidicolin was monitored. Plaque assays were performed in the presence of a range of concentrations (5 to 135 ,uM) of aphidicolin, and plaque sizes were compared with those in control assays; a total absence of macroscopic plaque formation was evident at 65 ,uM aphidicolin. A more quantitative assessment of the impact of aphidicolin on viral replication was obtained by titrating the virus harvested 24 h after infection of confluent monolayers at an MOI of 0.3. As shown in Fig. 1A , aphidicolin exerted a dramatic and dose-dependent inhibition of viral replication; in the presence of 75 or 90 ,uM drug, 0.005 or 0.0005% of control levels of virus was produced, respectively. Based on these two assays of drug efficacy, a dosage of 85 ,uM aphidicolin was chosen for further studies.
Isolation of Aphr virus from a mutagenized viral stock. Wt vaccinia virus was mutagenized in vivo with nitrosoguanidine as previously described (8); briefly, confluent monolayers containing 4 x 107 cells were infected at an MOI of 10 and exposed to the mutagen during part of the replicative cycle. Although this level of mutagenesis had only a minimal effect on virus viability as assayed by yield, the success of the mutagenesis procedure was evidenced by the 110-fold increase observed in the frequency of PAA' mutants following mutagenesis (data not shown). Within the mutagenized stock, the frequency of viruses with resistance to the chosen dose of 85 p.M aphidicolin was 5 x 104 PFU/1.4 x 109 total PFU, or 3.6/105 PFU. By comparing these titrations with those of unmutagenized stocks, we can estimate that a minimum of 98.7% of these resistant viruses were generated during the mutagenesis procedure. If one makes the oversimplifying assumptions that each infected cell produced an equivalent yield of virus following mutagenesis and that each (Fig. 2) . In each case, only the central HaeIII-HincII fragment was successful in this assay ( Table 1) .
The complete DNA sequences of the 500-bp HaeIIIHincII fragments derived from the five isolates were determined. The results are shown in Fig. 3 . In each case, the sole divergence from the wt DNA polymerase sequence was a single nucleotide change within the codon responsible for amino acid 498 of the vaccinia virus DNA polymerase (12, 38, 39) . In AR 5, 8, 11, and 12, identical G-A transitions in the first position (nucleotide 1492) were seen. These transitions were predicted to direct the substitution of a threonine for the wt alanine. In AR 9, a C-T transition observed in the second position (nucleotide 1493) resulted in the substitution of a valine for the wt alanine. Because of the surprising redundancy of the mutations, partial sequence data were obtained for the other five aphidicolin-resistant isolates (AR 3, 6, 7, 10, and 14). These five isolates all contained the G-A transition at nucleotide 1492 seen in AR 5, 8, 11, and 12. Preliminary phenotypic analyses of Aphr mutants: determination of mutation rate. It has been observed with other systems that genetic resistance to polymerase inhibitors presumed to interact with the nucleotide-binding domain is sometimes associated with altered polymerase fidelity (17, 18, 20, 28, 32) . In this context, the Aphr isolates were investigated for alterations in mutation rate by assaying the spontaneous frequency of viral mutants resistant to PAA, IBT, and rifampin. IBT causes a degradation of mRNA and rRNA during the late stages of poxvirus infection (33) , whereas rifampin inhibits polypeptide-processing events associated with virion morphogenesis (16, 23) . Resistance to each of these three drugs has been associated with nucleotide changes in individual genes (1, 12a, 37) . In duplicate experiments, wt and Aphr stocks were titrated in the pres- ence of inhibitory concentrations of drug, and the frequency of large, resistant plaques was measured. Because these experiments were initiated before molecular analyses of the mutant lesions were complete, all five well-studied mutants were included in this study. These results are shown in Table  2 . Comparison of the duplicate experiments indicates that the values obtained for each isolate were quite reproducible. The most striking result was the dramatic increase in mutant frequency apparent in the AR 9 stock. The other four stocks exhibited a range of mutation rates, with AR 8 most like wt, AR 11 and AR 12 showing similarly elevated frequencies of Rif', and AR 5 exhibiting increased frequencies of both Rif' and IBTr.
Observation of this range of phenotypes made us suspect that additional extra-or intragenic mutations might have been sustained in some or all of these individual isolates during the initial nitrosoguanidine treatment. To allow a rigorous examination of the impact of each Aphr lesion on the virus, it seemed advantageous to isolate congenic viral strains which differed only in the polymerase lesion.
Isolation of congenic viral strains carrying the Aphr lesions in an unmutagenized, wt background. Cultures were infected with wt virus and transfected with the minimal 500-bp HaeIII-HincII fragment ( Fig. 2 Table 3 . It is clear that ARP-9 (Ala-to-Val mutation) stocks again showed a significantly increased frequency of PAAr, Rif, and IBT' mutants; the increase for the last two drugs, which do not interact with the DNA polymerase, is higher than that seen for PAA. The rate of mutation appeared somewhat higher in the stock amplified in the presence of drug, especially regarding the generation of PAA' mutants. The other Aphr strains (Ala-toThr mutations) appeared to have mutation rates indistinguishable from those of the wt virus. The constant values obtained with the last four congenic strains, shown subsequently by sequence analysis to contain identical Aphr lesions, strengthened our confidence in the significance of the elevated mutation rate observed in the ARP-9 stocks. In addition, comparison of this constancy with the variability observed during analysis of the original AR 26, 31, 41) . Therefore, the sensitivities of ARP-9 and ARP-12 to PAA, araC, and araA were investigated. PAA is thought to interfere with the exchange of PPi and deoxynucleoside triphosphates within the nucleotide-binding domain of the polymerase; araC and araA are nucleoside analogs of cytosine and adenosine, respectively. Initially, plaque assays of wt, ARP-9, and ARP-12 stocks were performed in parallel in the presence of increasing concentrations of each drug. Comparison of plaque sizes in the presence of various concentrations of PAA or araA revealed that ARP-9 was significantly hypersensitive to these drugs and ARP-12 was mildly hypersensitive (data not shown). Both mutants showed a moderate hypersensitivity to araC. These phenotypes were further evaluated by measuring the viral yield obtained at 24 h p.i. with wt, ARP-9, or ARP-12 at an MOI of 1 in the presence of several concentrations of PAA, araC, or araA. These results are presented in Fig. 5 .
The extreme hypersensitivity of ARP-9 to PAA is evident; at a drug concentration of 50 ,ug/ml, ARP-9 yield was reduced to 0.02% of the control value, whereas wt yields were diminished only to 30%. At 100 ,ug of PAA per ml, ARP-12 yield was reduced to 0.4% of the control value, whereas wt was 10-fold less sensitive and 4% of control levels of virus were harvested. ARP-9 and ARP-12 showed similar hypersensitivities to araC; in the presence of various concentrations of drug, inhibition of the mutant stocks was 10-to 25-fold more severe than that observed for wt stocks.
(Comparison of these two assays of drug sensitivity revealed that macroscopic plaques were no longer apparent when viral yield dropped below 2% of control levels.) In [31] .) That the appearance of drugresistant viral progeny reflects bona fide mutational events rather than amplification of genes encoding the targets of the specific drugs is supported by our inability to detect any variation in the molarity or mobility of restricted genomic DNA fragments isolated from the mutant stocks (data not shown).
There is ample precedent for an association of altered polymerase fidelity with altered polymerase sensitivity to drugs that interact with the nucleotide-binding domain. Mutator and antimutator isolates of HSV-1, HSV-2, and CHO cells have been associated with structural changes in the DNA polymerase nucleotide-binding domain (17, 20, 28, 31, 32, 41 Biochemical confirmation of these predictions awaits the overexpression and purification of the mutant DNA polymerase molecules. The studies described in this report shed new light on the pharmacological properties of the vaccinia virus DNA polymerase and suggest that the vaccinia virus enzyme may be a good model system for probing crossresistance and mutually exclusive drug resistance. In addition, these genetic findings provide clues as to the residues of the enzyme involved in forming the nucleotide-binding domain and offer an intriguing system for probing the basis of polymerase fidelity.
